Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy

Downstream ERK kinase appears to be the Achilles' Heel of the MAPK pathway. Targeting ERK kinase provides potential therapeutic opportunities for a broad spectrum of cancers bearing RAS, RAF and MEK mutations as well as those with acquired resistance to BRAF and MEK inhibitors (RAFi and MEKi).109